Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stanford V Chemotherapy with Tailored-Field Radiation for Pediatric Hodgkin Lymphoma
NCT00352027Phase 2Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Jul 2006
- Primary completion
- May 2015
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin, vinblastine, mechlorethamine, cyclophosphamide, vincristine sulfate liposome injection and 3 more in Hodgkin lymphoma (HL), sponsored by St. Jude Children's Research Hospital. Primary endpoint: Event-Free Survival Probability at 3 years. Started Jul 2006; status: completed.
02
Drugs
pegylated liposomal doxorubicinvinblastinemechlorethaminecyclophosphamidevincristine sulfate liposome injection
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT00352027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00352027.